May 1, 2020 / 11:13 AM / a month ago

BRIEF-U.S. FDA Accepts For Priority Review Bristol Myers Squibb’s Application For Acute Myeloid Leukemia Treatment

May 1 (Reuters) - Bristol-Myers Squibb Co:

* U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS FOR PRIORITY REVIEW BRISTOL MYERS SQUIBB’S APPLICATION FOR CC-486 FOR MAINTENANCE TREATMENT OF ADULT PATIENTS IN REMISSION WITH ACUTE MYELOID LEUKEMIA

* BRISTOL-MYERS SQUIBB CO - U.S. FDA SET TARGET ACTION DATE OF SEPTEMBER 3, 2020 FOR CC-486 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below